Paul A. Bunn, Jr., MD, discusses subsets of patients with lung cancer that can benefit more from enrolling on clinical trials with immunotherapy compared with patients who do not benefit as much from immunotherapeutic approaches. Immunotherapy does not work in every patient, Bunn notes.
Paul A. Bunn, Jr., MD, Distinguished Professor, James Dudley Chair in Lung Cancer Research, Division of Medical Oncology, University of Colorado Denver, discusses subsets of patients with lung cancer that can benefit more from enrolling on clinical trials with immunotherapy compared with patients who do not benefit as much from immunotherapeutic approaches. Immunotherapy does not work in every patient, Bunn notes.
Patients who are never-smokers or who harbor a molecular driver, such asEGFR,ALK,ROS1, orTRK, will have a higher response rate with oral agents, such as tyrosine kinase inhibitors (TKIs). The best approach to enrolling patients on clinical trials is to determine which patients have molecular drivers and exclude those patients from neoadjuvant immunotherapy trials since they are less likely to benefit from treatment. For these patients, there will be another treatment that could be more beneficial to them.
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
March 25th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More